Table of ContentsIntroductionRead (pg. 5)Pharma Deals & TrendsRead (pg. 6)MethodologyRead (pg. 7)Gilead and LEO PharmaRead (pg. 8)Merck & Co. and EpitopeaRead (pg. 9)AstraZeneca and AlteogenRead (pg. 10)Ono Pharmaceutical & Ionis PharmaceuticalsRead (pg. 11)Vanda Pharmaceuticals and AnaptysBio Read (pg. 12)REGENXBIO and Nippon ShinyakuRead (pg. 13)Mediar Therapeutics and Eli Lilly and CompanyRead (pg. 14)Alchemab Therapeutics and Eli Lilly and CompanyRead (pg. 15)Eli Lilly and Company and Scorpion TherapeuticsRead (pg. 16)1cBio Inc. and Alesta TherapeuticsRead (pg. 17)Chugai Pharmaceutical and Araris BiotechRead (pg. 18)Variant Bio and Novo NordiskRead (pg. 19)Lantheus and Evergreen TheragnosticsRead (pg. 20)Salarius Pharmaceuticals and Decoy TherapeuticsRead (pg. 21)Novartis and Anthos Therapeutics, Inc.Read (pg. 22)Novartis and Regulus TherapeuticsRead (pg. 23)Mallinckrodt plc and Endo, Inc.Read (pg. 24)Alumis Inc and Acelyrin, Inc.Read (pg. 25)Jazz Pharmaceuticals plc and Chimerix, Inc.Read (pg. 26)Intas Pharmaceuticals and Coherus BioSciences IncRead (pg. 27)Major Pharmaceutical Deals in 2025Read (pg. 28)Pharma Deals in FocusRead (pg. 29)ConclusionRead (pg. 30)ReferencesRead (pg. 32)Pharma Insight Reportshttps://adisinsight.springer.com/insight-hub